MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward the commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with an initial focus on industrial safety applications in South America's mining sector. The company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments.
Leyton brings extensive experience in national drug policy and workplace safety, having helped design and implement Chile's 'Zero Tolerance' alcohol-impaired driving law as part of the country's alcohol prevention framework. He also played a role in establishing Chile's roadside drug testing program introduced in 2019. His appointment reflects MindBio's strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements.
MindBio's AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication in a range of enterprise environments including the mining industry, aviation, construction, and law enforcement.
According to the company, the move into South America's mining sector is a key step, as the region's mining industry faces significant safety challenges related to impairment. The technology could help reduce accidents and improve compliance with workplace safety regulations. For more details, view the full article at https://ibn.fm/JBNVq.
The latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF.
